Cross Country Healthcare, Inc. (CCRN) Q2 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: strong cash flow, share repurchases, and positive guidance on demand increase are offset by significant revenue decline, competitive pressures, and a substantial bad debt expense. The Q&A reveals optimism about demand but acknowledges competitive challenges and cost pressures. The neutral rating reflects these balanced positives and negatives, with no strong catalyst for significant stock price movement.
Key Financial Performance
Consolidated Revenue $340 million, down 37% year-over-year, driven primarily by declines in travel and local assignments in large acute care settings.
Gross Profit $71 million, with a gross margin of 20.8%. Gross margin was down 200 basis points year-over-year due to higher lodging subsidies and costs related to health insurance, workers' comp, and professional liability.
Selling, General and Administrative Expense (SG&A) $60 million, down 24% year-over-year, primarily due to lower salary and benefit costs associated with reductions in headcount.
Adjusted EBITDA $14 million, representing an adjusted EBITDA margin of 4.2%, near the high end of guidance, despite a bad debt charge of $19 million.
Income Tax Benefit $3.5 million, driven primarily by the bad debt charge.
Physician Staffing Revenue $48 million, up 7% year-over-year and 3% sequentially, reflecting an increase in billable days and favorable mix.
Homecare Staffing Revenue Up 12% year-over-year, driven by recent PACE program wins.
Cash from Operations $82 million, reflecting strong collections from clients.
Cash Position $70 million in cash with no outstanding debt.
Share Repurchases Nearly 1 million shares repurchased for approximately $15 million in the second quarter.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Intellify Technology: Continued investment in the client-facing Workforce Solutions platform, Intellify, which has gained critical mass with over 40 clients across 500 facilities and more than 5,500 active users.
SaaS-based Subscription: First SaaS-based subscription awarded to a third-party utilizing Intellify technology.
Travel Demand: Travel demand has increased by more than 20% since the start of Q2 2024, with a rise in orders and open order rates.
Physician Staffing Revenue: Physician staffing reported a record $48 million in revenue for a single quarter, up 7% year-over-year.
Homecare Business Growth: Homecare business revenue increased by double digits year-over-year, driven by recent wins and program implementations.
Cost Management: Reduced U.S. headcount by over 20% in 2024 to align with demand and preserve profitability.
ERP Implementation: First phase of ERP implementation is live, with the second phase expected to complete by mid-2025.
Share Repurchase: Repurchased nearly 1 million shares in Q2 2024, totaling 5 million shares since August 2022.
M&A Opportunities: Actively exploring M&A opportunities to diversify and enhance technological capabilities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Competitive Pressures: The company is operating in a very competitive environment for talent, which is impacting margins due to the need to remain competitive on both bill rates and pay rates.
Regulatory Issues: There are no specific regulatory issues mentioned, but the company acknowledges the impact of higher costs related to health insurance, workers' compensation, and professional liability.
Supply Chain Challenges: Lodging subsidies and insurance costs are continuing to pressure margins, indicating challenges in managing operational costs.
Economic Factors: The company is experiencing a decline in travel and local assignments, with revenue down 10% sequentially and 37% year-over-year, primarily due to softer demand for contingent clinical labor.
Bankruptcy Impact: A bad debt expense of $19 million was reported due to a bankruptcy from a single MSP client, which had a significant impact on the financials.
Headcount Reductions: The company has reduced its U.S. headcount by more than 20% to align with market demand, which poses risks related to operational capacity and employee morale.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Travel Demand: Travel demand has been steadily rising, up more than 20% relative to the start of the second quarter.
Cost Management: Over the last 18 months, the company has reduced U.S. headcount by more than 20% to align with demand.
Technology Investment: Continued investment in technology, particularly the Intellify platform, which has gained critical mass with over 40 clients.
M&A Opportunities: The company is actively exploring M&A opportunities to diversify and enhance technological capabilities.
Q3 Revenue Guidance: Anticipated revenue between $305 million and $315 million.
Q3 Adjusted EBITDA Guidance: Expected adjusted EBITDA between $10 million and $13 million.
Adjusted EBITDA Margin: Targeting a high single-digit adjusted EBITDA margin in the long term, with mid-single digits expected in the near term.
Share Repurchase: Repurchased nearly 1 million shares in Q2, totaling 5 million shares since August 2022.
Future Growth Outlook: Expecting sequential revenue growth in Q4, driven by improving travel demand and strong performance in other business lines.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: Cross Country Healthcare repurchased nearly 1 million shares in the second quarter of 2024, totaling approximately $15 million. Since August 2022, the company has repurchased a total of 5 million shares under its $100 million share repurchase plan.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide more insight into the volume outlook and demand for Q4?
A:We've seen demand steadily increase over the last couple of months, up 20% since the start of Q2, across a broad spectrum of specialties. This increase is not driven by winter needs, and we anticipate winter needs will come in later.
Q:What is the current state of contract growth versus new contract wins?
A:We had attrition earlier in 2023, but we are now on a better trajectory with positive net contract value over the last couple of quarters.
Q:What is the general consensus among clients regarding the increase in demand?
A:Clients are comfortable with their current labor mix and are seeing higher acuity and census, driven by deferred healthcare needs post-COVID.
Q:Have you received indications from clients regarding their winter needs?
A:Clients are waiting longer than usual to provide winter needs, which we expect to receive closer to September.
Q:What are your thoughts on operating margins for the nurse and allied segment?
A:While bill pay spreads have improved, they are muted by elevated housing costs. Future margin improvements will come from a better mix of business and efficiencies.
Q:How do you see the competitive landscape evolving?
A:The market remains competitive, and smaller companies may struggle without MSPs or VMSs. We expect some shakeout in the market.
Q:What is your outlook for cash flow and capital deployment?
A:We are focused on converting EBITDA to cash flow and are looking for M&A opportunities to diversify our portfolio.
Q:What is the potential for gross margin improvement in the coming quarters?
A:While there may be some incremental gross margin improvement, most will come from operational efficiencies and mix rather than bill rates.
Q:How are you managing rising insurance costs?
A:Insurance costs are partly out of our control, but we will know more about renewal rates in the upcoming quarter.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding the specific impact of lost contracts on current performance, stating that they do not disclose certain metrics due to the complexity of the situation.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI analytics
Cross Country
Hi
Homecare
bankruptcy
break
capital allocation
capture rate
case
claim
color
company
country
couple month
date
demand couple
demand increase
driver
element
environment
experience
healthcare
hire
increase order
increase winter
margin improvement
opening
order winter
placement
portfolio
portion
premium
rate order
ratio
renewal rate
resource pool
sale production
school
subsidy
variance
view
winter need
winter order
CCRN Transcript
Cross Country Healthcare, Inc. (CCRN) Q3 2024 Earnings Call Transcript
Unknown11-7
The earnings call reveals several challenges: revenue and gross profit declines, competitive pressures, and margin compression. Despite share repurchases, the financial performance is weak with declining revenue and pressured margins. The Q&A highlights concerns about margin pressures and unclear future guidance, indicating potential uncertainties. The market strategy and financial health ratings are negatively impacted by these factors, leading to an overall negative sentiment.
Cross Country Healthcare, Inc. (CCRN) Q2 2024 Earnings Call Transcript
Unknown8-1
The earnings call presents a mixed picture: strong cash flow, share repurchases, and positive guidance on demand increase are offset by significant revenue decline, competitive pressures, and a substantial bad debt expense. The Q&A reveals optimism about demand but acknowledges competitive challenges and cost pressures. The neutral rating reflects these balanced positives and negatives, with no strong catalyst for significant stock price movement.
Cross Country Healthcare, Inc. (CCRN) Q1 2024 Earnings Call Transcript
Neutral5-2
Cross Country Healthcare, Inc. (CCRN) Q1 2024 Earnings Call Transcript
Unknown5-2
The earnings call highlights several negative trends, including declining revenue in the Nurse and Allied business, increasing DSO, and gross margin underperformance. Despite some optimism about the Locum business and technology investments, the lack of clear guidance and significant challenges in key segments overshadow positive aspects. Q&A further emphasizes demand softness and management's vague responses, leading to a negative sentiment. With no market cap data, the reaction could vary, but the overall sentiment leans negative due to the revenue decline and uncertainties.
CCRN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
